What MITEM Pharma does

MITEM Pharma is a French private pharmaceutical laboratory (SAS Mitem Pharma) headquartered in Massy, France, that specializes in Medicines of Major Therapeutic Interest (MITMs) — drugs essential to life that are typically neglected by large pharmaceutical groups due to commercial unattractiveness. Founded in 2016 by Claude-Alain Cudennec and Eric Thierry, the company identifies abandoned treatments in collaboration with partner physicians and patient associations, then acquires worldwide rights to these drugs, re-valorizes them, secures supply chains, and commercializes them. The company operates across three therapeutic verticals: endocrinology, emergency cardiology, and medical dermatology.

The portfolio includes proprietary generics (MELADININE® vitiligo treatments, PROPRANOLOL ACETLAB injectable, DEMECLOCYCLINE ACETLAB, FLUDROCORTISONE ACETLAB) and globally recognized acquired brands (DESFERAL®/deferoxamine from Novartis in September 2024, FLISINT® from Sanofi in February 2025). The company distributes through standard pharmaceutical supply chains to hospitals, pharmacies, and healthcare providers across 15 countries on 3 continents. The team of 11-50 employees is led by deep pharma industry veterans, with a CFO appointed in June 2025 to support continued scaling.

Revenue is generated through one-time licensing/acquisition of drug rights followed by ongoing commercialization via field sales targeting healthcare professionals and patient associations. Pricing is negotiated within standard pharmaceutical distribution channels and is not publicly disclosed. In April 2022, Techlife Capital invested €10 million (with potential up to €30 million) via a private equity round combining capital increase and share buybacks, taking control of the laboratory. Reported revenue stood at €5 million in 2022, with subsequent portfolio acquisitions and geographic expansion likely driving meaningful top-line growth since.

Name

MITEM Pharma

Legal name

SAS Mitem Pharma

Website

https://mitempharma.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

MITEM Pharma is a French private pharmaceutical laboratory that acquires, re-valorizes, and commercializes Medicines of Major Therapeutic Interest (MITMs) — essential but neglected drugs — across endocrinology, emergency cardiology, and dermatology, serving healthcare providers and patients in 15 countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Specialty pharmaceuticals
• Essential medicines
• Neglected drug re-valorization
• Rare disease therapeutics
• Pharmaceutical manufacturing

Headquarters

HQ city

Massy

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: MITEM Pharma generates revenue through the development, marketing, and commercialization of Medicines of Major Therapeutic Interest (MITMs). The company acquires rights to neglected drugs, revalues them, and sells them to healthcare providers and patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

MITEM Pharma is a French pharmaceutical laboratory that develops, acquires, re-valorizes, and commercializes Medicines of Major Therapeutic Interest (MITMs) — essential drugs often neglected by larger pharmaceutical groups. The company operates across three therapeutic areas: endocrinology, emergency cardiology, and medical dermatology, distributing products through standard pharmaceutical supply chains to healthcare providers and hospitals across 15 countries on 3 continents.

Product overview

MITEM Pharma is a French pharmaceutical laboratory specializing in MITMs (Médicaments d'Intérêt Thérapeutique Majeur - Medicines of Major Therapeutic Interest). The company focuses on revitalizing and commercializing neglected essential medications that are critical for patient survival and well-being. The product portfolio includes: Meladinine line (dermatology - vitiligo treatment), Propranolol Acetlab (cardiology), Demeclocycline Acetlab and Fludrocortisone Acetlab (endocrinology). Recent acquisitions include FLISINT® from SANOFI and worldwide rights to DESFERAL® from NOVARTIS. MITEM Pharma operates in three therapeutic areas: endocrinology, emergency cardiology, and medical dermatology.

Differentiator

Problem solved

Functional benefit

Products and services

• MELADININE 10 mg, comprimé (tablet) Meladinine 10 mg tablet used for the treatment of vitiligo, a dermatological condition. Targeted at healthcare providers and patients requiring dermatological treatments.
• MELADININE 0.75%, solution for local application Meladinine 0.75% topical solution for local application in dermatology treatment. Targeted at healthcare providers treating patients with dermatological conditions.
• MELADININE 0.1%, solution for local application Meladinine 0.1% topical solution for local application in dermatology treatment. Targeted at healthcare providers treating patients with dermatological conditions.
• PROPRANOLOL ACETLAB 5 mg/5 mL, solution injectable Propranolol 5 mg/5 mL injectable solution for emergency cardiology applications. Targeted at hospitals and emergency cardiology departments.
• DEMECLOCYCLINE ACETLAB 150 mg, gélule (capsule) Demeclocycline 150 mg capsule for endocrinology treatment applications. Targeted at healthcare providers treating endocrine disorders.
• FLUDROCORTISONE ACETLAB 50 microgrammes, comprimé sécable (scored tablet) Fludrocortisone 50 microgram scored tablet, the first and only generic of FLUCORTAC 50 microgrammes, used in endocrinology for adrenal insufficiency treatment. Targeted at healthcare providers and pharmacies.
• DESFERAL® (deferoxamine) Desferal (deferoxamine) pharmaceutical product for chelation therapy. Acquired worldwide rights from Novartis, distributed to healthcare providers and hospitals.
• FLISINT® Pharmaceutical product acquired from Sanofi in February 2025, part of MITEM Pharma's strategy to revitalize neglected drugs of major therapeutic interest. Distributed through standard pharmaceutical supply chains.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and supporting.

• SanoficoreStrategic or Co-development Partner · 4 February 2025MITEM Pharma acquired FLISINT from Sanofi in February 2025, expanding its portfolio of essential medicines.
• NovartiscoreStrategic or Co-development Partner · 25 September 2024MITEM Pharma acquired worldwide rights to DESFERAL (deferoxamine) from Novartis with the support of Techlife Capital and MACSF.
• Partner doctors and patient associationssupportingOthersMITEM Pharma collaborates with partner doctors and patient associations to identify abandoned treatments, revalue and relaunch essential drugs, and ensure access to appropriate care.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Theramex: UK-headquartered specialty pharmaceutical company focused on women's health and other underserved therapeutic areas, with a model of acquiring and revitalizing neglected mature brands; comparable in scale and strategy to MITEM.

Direct peers

• Pierre Fabre: French specialty pharmaceutical and dermo-cosmetic group with a strong dermatology and oncology presence; directly comparable to MITEM given the leadership overlap (CEO Claude-Alain Cudennec previously led Pierre Fabre R&D) and similar French specialty-pharma identity.
• Ethypharm: French specialty pharmaceutical company focused on niche, essential and complex medicines, including central nervous system and pain therapies, with a similar Europe-centric specialty pharma model and history of in-licensing/divestiture transactions.
• Orphan Europe (Recordati Rare Diseases): Specialty pharma business dedicated to rare and neglected diseases in Europe, now part of Recordati; one of the closest analogues to MITEM's model of identifying, acquiring and commercializing low-promotion essential medicines.
• Arrow Génériques (Ethypharm group): French generics and specialty pharma business (part of the Ethypharm group) that revitalizes and markets mature molecules in France and Europe — directly comparable to MITEM's branded-generic and licensing approach (note: Souriya Ghadda, MITEM's Head of Regulatory Affairs, previously led export regulatory affairs at Arrow).
• Swedish Orphan Biovitrum (Sobi): Swedish specialty biopharma focused on rare diseases, with a business model of acquiring rights to under-served therapies (e.g., haematology, immunology) and building dedicated supply and patient access — closely analogous to MITEM's MITM focus.
• Ipsen: French specialty pharmaceutical company with a portfolio focused on niche therapeutic areas (oncology, neurology, rare diseases); comparable to MITEM as a French-headquartered specialty pharma operating across multiple underserved therapeutic franchises.
• Recordati: Italian specialty pharmaceutical group with a dedicated rare-disease business (Recordati Rare Diseases, formerly Orphan Europe), pursuing a similar strategy of acquiring and commercializing neglected or low-promotion specialty medicines across multiple therapeutic areas.

Broad incumbents

• Alexion (AstraZeneca Rare Disease): Rare-disease specialist now part of AstraZeneca, focused on acquiring and developing therapies for underserved patient populations; comparable to MITEM in its mission-driven, niche-therapeutic approach but operating at far greater scale.
• Lundbeck: Danish specialty pharmaceutical company focused on brain diseases, with a broader and more mature specialty-pharma platform than MITEM; comparable as an established European specialty pharma, though operating at significantly greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mitem-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MITEM Pharma